Jover Placid 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Aug 5, 2025
Insider Transaction Report
Form 4
Jover Placid
See "Remarks"
Transactions
- Exercise/Conversion
Ordinary Shares
2025-08-01+12,827→ 12,827 total - Sale
Ordinary Shares
2025-08-01$15.16/sh−6,053$91,748→ 6,774 total - Exercise/Conversion
Restricted Share Units
2025-08-01−12,827→ 38,484 total→ Ordinary Shares (12,827 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.13 to $15.31, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]Restricted share units were granted on August 1, 2024, with 12,827 vested on August 1, 2025, 12,827 vesting on each of August 1, 2026 and August 1, 2027, and 12,830 vesting on August 1, 2028.